Bristol Myers Squibb to present positive new data on lymphoma treatment
Ella Day | June 18, 2025 | News story | Medical Communications, Research and Development | Bristol Myers Squibbs, CAR T-cell therapy, International Conference on Malignant Lymphoma, Oncology, relapsed or refractory marginal zone lymphoma
Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory marginal zone lymphoma (MZL). The new data will be presented at the International Conference on Malignant Lymphoma, Lugano, Switzerland, on 19 June, building on data announced in February.
Breyanzi demonstrated significant clinical efficacy as 95.5% of patients with relapsed or refractory MZL treated with Breyanzi achieved a response, with 62.1% achieving complete response and 88.6% maintaining a response at 24 months. Specifically, 85.7% achieved progression-free survival, and 90.4% overall survival. The candidate maintained a consistent safety profile and no new safety signals were identified.
The results “underscores the potential of this one-time therapy to significantly improve patient outcomes,” said M Lia Palomba, TRANSCEND FL study investigator and lymphoma and cell therapy specialist at Memorial Sloan Kettering Cancer Center, New York, US.
MLZ is characterised by clustered white blood cells together in lymph nodes or organs. Relapse is common and currently the median survival rate for patients with multiple relapses is three to five years, indicating a need for the development of more effective therapies.
Breyanzi is a CD19-directed CAR T-cell therapy which enhances the expansion and persistence of CAR T-cells. Using patients’ own T-cells, the treatment is delivered through a one-time infusion.
The data “reinforces [the company’s] commitment to unlock the full potential of cell therapy to help patients living with relapsed or refractory lymphomas,” added Rosanna Ricafort, vice president of BMS.
Ella Day
18/6/25
Related Content
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, …
